HBB and non-small cell lung carcinoma: Additionally, we observed downregulation of blood hemoglobin markers (HBA1, HBB, and HBD) and peroxiredoxins (PRDX1 and PRDX2) in patients with SCLC, which is opposite to the upregulated levels previously observed in lung cancer patients, predominantly in NSCLC patients [54, 55], except for PRDX2 which has been reported to be downregulated in NSCLC [56].